ADMA BIOLOGICS, INC. (ADMA) Total liabilities 2016–2025
ADMA BIOLOGICS, INC. (ADMA) total liabilities at each fiscal year-end, per SEC filings.
$146.9MFY2025 · since FY2016: $28.1M → $146.9M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $146.9M | +5.2% |
| FY2024 | $139.7M | -28.0% |
| FY2023 | $194.0M | -1.3% |
| FY2022 | $196.5M | +45.5% |
| FY2021 | $135.1M | +13.1% |
| FY2020 | $119.4M | +18.4% |
| FY2019 | $100.9M | +46.0% |
| FY2018 | $69.1M | +2.1% |
| FY2017 | $67.7M | +140.5% |
| FY2016 | $28.1M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice
More ADMA financial trends
ADMA RevenueADMA Net incomeADMA Net marginADMA Gross profitADMA Gross marginADMA Operating incomeADMA Operating marginADMA Operating cash flowADMA Free cash flowADMA Capital expendituresADMA Return on equityADMA Stock buybacksADMA Dividends paidADMA Total assetsADMA Shareholders’ equityADMA overview →